Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023)
Contineum Therapeutics (CTNM) recorded quarterly Amortization of Deferred Charges of -$1000.0 in Q4 2023, up 99.55% quarter-over-quarter from -$223000.0 in Q2 2023.
Contineum Therapeutics (CTNM) Amortization of Deferred Charges (2023) Analysis & Trends
Contineum Therapeutics' Amortization of Deferred Charges history runs 1 years deep, the most recent figure standing at -$1000.0 for Q4 2023.
- In Q4 2023, Amortization of Deferred Charges changed N/A year-over-year to -$1000.0; the TTM figure through Sep 2024 stood at -$1000.0 (changed N/A YoY), while the FY2023 annual figure was -$198000.0, changed N/A from the prior year.
- Amortization of Deferred Charges was -$1000.0 for Q4 2023 at Contineum Therapeutics, up from -$223000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $26000.0 in Q1 2023 to a low of -$223000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Jun 30, 2023 | -223,000.00 |
| Jun 30, 2023 | -223,000.00 |
| Mar 31, 2023 | 26,000.00 |
| Mar 31, 2023 | 26,000.00 |